Table of Content

1. Key Insights

2. Cystinuria: Market Overview at a Glance
2.1. Market Share (%) Distribution of Cystinuria in 2017
2.2. Market Share (%) Distribution of Cystinuria in 2028

3. Disease Overview: Cystinuria
3.1. Introduction
3.2. Classification
3.3. Clinical features
3.4. Genetics
3.5. Pathophysiology
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Prevalent Patient Population of Cystinuria
4.3. Country Wise-Epidemiology of Cystinuria
4.4. United States
4.4.1. Assumptions and Rationale
4.4.2. Prevalent Cases of Cystinuria in the United States
4.4.3. Gender-Specific Cases of Cystinuria in the United States
4.4.4. Age-Specific Cases of Cystinuria in the United States
4.4.5. Diagnosed Cases of Cystinuria in the United States
4.4.6. Type-Specific Cases of Cystinuria in the United States
4.5. EU5
4.5.1. Assumptions and Rationale
4.6. Germany
4.6.1. Prevalent Cases of Cystinuria in Germany
4.6.2. Gender-Specific Cases of Cystinuria in Germany
4.6.3. Age-Specific Cases of Cystinuria in Germany
4.6.4. Diagnosed Cases of Cystinuria in Germany
4.6.5. Type-Specific Diagnosed Cases of Cystinuria in Germany
4.7. France
4.7.1. Prevalent Cases of Cystinuria in France
4.7.2. Gender-Specific Cases of Cystinuria in France
4.7.3. Age-Specific Cases of Cystinuria in France
4.7.4. Diagnosed Cases of Cystinuria in France
4.7.5. Type-Specific Cases of Cystinuria in France
4.8. Italy
4.8.1. Prevalent Cases of Cystinuria in Italy
4.8.2. Gender-Specific Cases of Cystinuria in Italy
4.8.3. Age-Specific Cases of Cystinuria in Italy
4.8.4. Diagnosed Cases of Cystinuria in Italy
4.8.5. Type-Specific Cases of Cystinuria in Italy
4.9. Spain
4.9.1. Prevalent Cases of Cystinuria in Spain
4.9.2. Gender-Specific Cases of Cystinuria in Spain
4.9.3. Age-Specific Cases of Cystinuria in Spain
4.9.4. Diagnosed Cases of Cystinuria in Spain
4.9.5. Type-Specific Cases of Cystinuria in Spain
4.10. United Kingdom
4.10.1. Prevalent Cases of Cystinuria in United Kingdom
4.10.2. Gender-Specific Cases of Cystinuria in the United Kingdom
4.10.3. Age-Specific Cases of Cystinuria in the United Kingdom
4.10.4. Diagnosed Cases of Cystinuria in the United Kingdom
4.10.5. Type-Specific Diagnosed Cases of Cystinuria in the United Kingdom
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Prevalent Cases of Cystinuria in Japan
4.11.3. Gender-Specific Cases of Cystinuria in Japan
4.11.4. Age-Specific Cases of Cystinuria in Japan
4.11.5. Diagnosed Cases of Cystinuria in Japan
4.11.6. Type-Specific Diagnosed Cases of Cystinuria in Japan

5. Current Treatment Practices
5.1. The European Association of Urology (EAU) Guidelines

6. Unmet Needs

7. Marketed Drugs
7.1. Cuprimine (d-penicillamine): Bausch Health
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Other Development Activities
7.1.4. Product Profile
7.2. Tiopronin (Thiola): Mission Pharmacal/ Retrophin
7.2.1. Drug Description
7.2.2. Regulatory Milestones
7.2.3. Other Developmental Activities
7.2.4. Safety and Efficacy
7.2.5. Product Profile

8. Emerging Therapies
8.1. Key Cross Competition
8.2. ADV7103: Advicenne
8.2.1. Drug Description
8.2.2. Other Developmental Activities
8.2.3. Clinical Development
8.2.4. Product Profile
8.3. Bucillamine: Revive Therapeutics
8.3.1. Drug Description
8.3.2. Other Developmental Activities
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
8.4. Tolvaptan: Otsuka Pharmaceutical
8.4.1. Drug Description
8.4.2. Clinical Development
8.4.3. Safety and Efficacy
8.4.4. Product Profile

9. Cystinuria: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Cystinuria in 7MM

10. Market Outlook by Country

11. The United States: Market Outlook
11.1. United States Market Size
11.1.1. Total Market Size of Cystinuria
11.1.2. Market Size of Cystinuria by Therapies

12. EU-5 Countries: Market Outlook
12.1. Germany
12.1.1. Total Market Size of Cystinuria
12.1.2. Market Size of Cystinuria by Therapies
12.2. France
12.2.1. Total Market Size of Cystinuria
12.2.2. Market Size of Cystinuria by Therapies
12.3. Italy
12.3.1. Total Market Size of Cystinuria
12.3.2. Market Size of Cystinuria by Therapies
12.4. Spain
12.4.1. Total Market Size of Cystinuria
12.4.2. Market Size of Cystinuria by Therapies
12.5. United Kingdom
12.5.1. Total Market Size of Cystinuria
12.5.2. Market Size of Cystinuria by Therapies
12.6. Japan: Market Outlook
12.6.1. Total Market Size of Cystinuria
12.6.2. Market Size of Cystinuria by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix
15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight



List of Figures


Figure 1: Cellular localization and function of rBAT (SLC3A1) and b0,+AT (SLC7A9)
Figure 2: Genomic structure and putative function of the encoded protein regions of the Cystinuria genes
Figure 3: Trafficking of cystine and dibasic amino acids in epithelial cells of the renal proximal tubule or small intestine
Figure 4: Diagnostic algorithm of Cystinuria
Figure 5: Prevalent Patient Population of Cystinuria in 7MM (2017–2028)
Figure 6: Prevalent Cases of Cystinuria in the United States (2017–2028)
Figure 7: Gender-Specific Cases of Cystinuria in the United States (2017–2028)
Figure 8: Age-Specific Cases of Cystinuria in the United States (2017–2028)
Figure 9: Diagnosed Cases of Cystinuria in the United States (2017–2028)
Figure 10: Type-Specific Cases of Cystinuria in the United States (2017–2028)
Figure 11: Prevalent Cases of Cystinuria Germany (2017–2028)
Figure 12: Gender-Specific Cases of Cystinuria in Germany (2017–2028)
Figure 13: Age-Specific Cases of Cystinuria in Germany (2017–2028)
Figure 14: Diagnosed Cases of Cystinuria in Germany (2017–2028)
Figure 15: Type-Specific Cases of Cystinuria in Germany (2017–2028)
Figure 16: Prevalent Cases of Cystinuria in France (2017–2028)
Figure 17: Gender-Specific Cases of Cystinuria in France (2017–2028)
Figure 18: Age-Specific Cases of Cystinuria in France (2017–2028)
Figure 19: Diagnosed Cases of Cystinuria in France (2017–2028)
Figure 20: Type-Specific Cases of Cystinuria in France (2017–2028)
Figure 21: Prevalent Cases of Cystinuria in Italy (2017–2028)
Figure 22: Gender-Specific Cases of Cystinuria in Italy (2017–2028)
Figure 23: Age-Specific Cases of Cystinuria in Italy (2017–2028)
Figure 24: Diagnosed Cases of Cystinuria in Italy (2017–2028)
Figure 25: Type-Specific Cases of Cystinuria in Italy (2017–2028)
Figure 26: Prevalent Cases of Cystinuria in Spain (2017–2028)
Figure 27: Gender-Specific Cases of Cystinuria in Spain (2017–2028)
Figure 28: Age-Specific Cases of Cystinuria in Spain (2017–2028)
Figure 29: Diagnosed Cases of Cystinuria in Spain (2017–2028)
Figure 30: Type-Specific of Cystinuria in Spain (2017–2028)
Figure 31: Prevalent Cases of Cystinuria in the United Kingdom (2017–2028)
Figure 32: Gender-Specific Cases of Cystinuria in the United Kingdom (2017–2028)
Figure 33: Age-Specific Cases of Cystinuria in the United Kingdom (2017–2028)
Figure 34: Diagnosed Cases of Cystinuria in the United Kingdom (2017–2028)
Figure 35: Type-Specific Cases of Cystinuria in the United Kingdom (2017–2028)
Figure 36: Prevalent Cases of Cystinuria in Japan (2017–2028)
Figure 37: Gender-Specific Cases of Cystinuria in Japan (2017–2028)
Figure 38: Age-Specific Cases of Cystinuria in Japan (2017–2028)
Figure 39: Diagnosed Cases of Cystinuria in Japan (2017–2028)
Figure 40: Type-Specific Cases of Cystinuria in Japan (2017–2028)
Figure 41: Treatment Algorithm of Cystinuria
Figure 42: Recommended algorithm of Cystinuria (EAU)
Figure 43: Unmet Needs
Figure 44: 7 Major Market Size of Cystinuria in USD Million (2017–2028)
Figure 45: Market Size of Cystinuria in the United States, USD Millions (2017–2028)
Figure 46: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 47: Market Size of Cystinuria in the Germany, USD Millions (2017–2028)
Figure 48: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 49: Market Size of Cystinuria in the France, USD Millions (2017–2028)
Figure 50: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 51: Market Size of Cystinuria in the Italy, USD Millions (2017–2028)
Figure 52: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 53: Market Size of Cystinuria in the Spain, USD Millions (2017–2028)
Figure 54: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 55: Market Size of Cystinuria in the UK, USD Millions (2017–2028)
Figure 56: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 57: Market Size of Cystinuria in the Japan, USD Millions (2017–2028)
Figure 58: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

 

List of Tables


Table 1: Phenotypic classification of cystinuria based on parental (heterozygote) findings
Table 2: Urinary cystine concentration
Table 3: Genotypic classification of Cystinuria
Table 4: Most common Cystinuria-associated mutations in rBAT*, SLC3A1, b0,+AT?, and SLC7A9
Table 5: Prevalent Patient Population of Cystinuria in 7MM (2017–2028)
Table 6: Prevalent Cases of Cystinuria in the United States (2017–2028)
Table 7: Gender-Specific Cases of Cystinuria in the United States (2017–2028)
Table 8: Age-Specific Cases of Cystinuria in the United States (2017–2028)
Table 9: Diagnosed Cases of Cystinuria in the United States (2017–2028)
Table 10: Type-Specific Cases of Cystinuria in the United States (2017–2028)
Table 11: Prevalent Cases of Cystinuria in Germany (2017–2028)
Table 12: Gender-Specific Cases of Cystinuria in Germany (2017–2028)
Table 13: Age-Specific Cases of Cystinuria in Germany (2017–2028)
Table 14: Diagnosed Cases of Cystinuria in Germany (2017–2028)
Table 15: Type-Specific Cases of Cystinuria in Germany (2017–2028)
Table 16: Prevalent Cases of Cystinuria in France (2017–2028)
Table 17: Gender-Specific Cases of Cystinuria in France (2017–2028)
Table 18: Age-Specific Cases of Cystinuria in France (2017–2028)
Table 19: Diagnosed Cases of Cystinuria in France (2017–2028)
Table 20: Type-Specific Cases of Cystinuria in France (2017–2028)
Table 21: Prevalent Cases of Cystinuria in Italy (2017–2028)
Table 22: Gender-Specific Cases of Cystinuria in Italy (2017–2028)
Table 23: Age-Specific Cases of Cystinuria in Italy (2017–2028)
Table 24: Diagnosed Cases of Cystinuria in Italy (2017–2028)
Table 25: Type-Specific Cases of Cystinuria in Italy (2017–2028)
Table 26: Prevalent Cases of Cystinuria in Spain (2017–2028)
Table 27: Gender-Specific Cases of Cystinuria in Spain (2017–2028)
Table 28: Age-Specific Cases of Cystinuria in Spain (2017–2028)
Table 29: Diagnosed Cases of Cystinuria in Spain (2017–2028)
Table 30: Type-Specific Cases of Cystinuria in Spain (2017–2028)
Table 31: Prevalent Cases of Cystinuria in the United Kingdom (2017–2028)
Table 32: Gender-Specific Cases of Cystinuria in the United Kingdom (2017–2028)
Table 33: Age-Specific Cases of Cystinuria in the United Kingdom (2017–2028)
Table 34: Diagnosed Cases of Cystinuria in the United Kingdom (2017–2028)
Table 35: Type-Specific Cases of Cystinuria in the United Kingdom (2017–2028)
Table 36: Prevalent Cases of Cystinuria in Japan (2017–2028)
Table 37: Gender-Specific Cases of Cystinuria in Japan (2017–2028)
Table 38: Age-Specific Cases of Cystinuria in Japan (2017–2028)
Table 39: Diagnosed Cases of Cystinuria in Japan (2017–2028)
Table 40: Type-Specific Cases of Cystinuria in Japan (2017–2028)
Table 41: Methods to prevent recurrent cystine lithiasis*
Table 42: Dosing of cystine-binding thiol-containing medications (information derived from Micromedex, Lexicomp)
Table 43: Recommended surgical treatment of cystine stones as defined by stone size
Table 44: Grades of Recommendations for the treatment of cystine stones
Table 45: Recommendations for the treatment of cystine stones
Table 46: Key cross competition
Table 47: ADV7103, Clinical Trial Description, 2019
Table 48: Bucillamine, Clinical Trial Description, 2019
Table 49: Tolvaptan, Clinical Trial Description, 2019
Table 50: 7 Major Market Size of Cystinuria in USD Million (2017–2028)
Table 51: United States Market Size of Cystinuria in USD Million (2017–2028)
Table 52: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Table 53: Germany Market Size of Cystinuria in USD Million (2017–2028)
Table 54: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Table 55: France Market Size of Cystinuria in USD Million (2017–2028)
Table 56: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Table 57: Italy, Market Size of Cystinuria in USD Million (2017–2028)
Table 58: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Table 59: Spain, Market Size of Cystinuria in USD Million (2017–2028)
Table 60: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Table 61: UK Market Size of Cystinuria in USD Million (2017–2028)
Table 62: Market Size of Cystinuria by Therapies in USD Million (2017–2028)
Table 63: Japan, Market Size of Cystinuria in USD Million (2017–2028)
Table 64: Market Size of Cystinuria by Therapies in USD Million (2017–2028)